IP Library › Granted Patent US 10,668,000
Granted Patent B2
US 10,668,000 · App. 15/312,402 · Granted Jun 2, 2020

Peptides, compositions comprising them and uses in particular cosmetic uses

Inventors: Olivier Peschard (Saint Prest, FR); Anne Doucet (Rambouillet, FR); Richard Leroux (Faverolles, FR); Philippe Mondon (Montrouge, FR)
Assignee: SEDERMA
A61K8/64A61Q19/08C07K5/0823A61K38/00A61K2800/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,000
App. No.
15/312,402
Granted
Jun 2, 2020
Kind
B2
Abstract

The peptides have the general following formula: X-Pro*-Pro*-Xaa-Y in which: •Xaa is selected from Leucine (Leu, L), Arginine (Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D); •At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO 2 —R 1 ; •At the C terminal end of the peptide, Y is selected from OH, OR 1 , NH 2 , NHR 1 and NR 1 R 2 ; •R 1 and R 2 are, independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, and which skeletum can comprise an heteroatom, in particular an O, S and/or N atom; •Pro* correspond to a Proline, an analogue or derivative thereof; •if X is H then Y is selected from OR 1 , NH 2 , NHR 1 and NR 1 R 2 , and if Y is OH then X is —CO— or —SO 2 —R 1 ; and the peptide hypoxanthine-Pro-Pro-Arg being excluded. The invention provides the use of the peptides of above formula I to stimulate the synthesis of the molecules constituting the dermal extracellular matrix, including collagen I and IV and elastin. A cosmetic treatment according to the invention includes anti-aging, anti-wrinkles, improving mechanical properties of the skin, firmness/tone/elasticity/suppleness/flexibility, increasing density and volume of the skin, restructuring effect, fighting stretch marks, improving skin barrier and/or skin hydration.

Claims (30)

1. A topical composition comprising:

an amount of between 0.000001% and 15%, relative to the total weight of the composition, of at least one peptide of the general following formula:

X-Pro*-Pro*-Xaa-Y  (I)

Xaa is selected from Leucine (Leu, L), Arginine (Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D);

at the N terminal end of the peptide, X is an acyl group CO—R 1 selected from octanoyl (C 8 ), decanoyl (C 10 ), lauroyl (C 12 ), myristoyl (C 14 ), palmitoyl (C 16 ), stearoyl (C 18 ), biotinoyl, elaidoyl, oleoyl and lipoyl;

at the C terminal end of the peptide, Y is selected from OH, OR 1 , NH 2 , NHR 1 and NR 1 R 2 ;

R 1 and R 2 , independently from each other, are selected from an alkyl, aryl, aralkyl, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, and which backbone can comprise an heteroatom;

Pro* is a Proline, an analogue or derivative thereof; and

a physiologically acceptable topical medium for a non-therapeutic cosmetic treatment or for a therapeutic treatment.

2. The topical composition according to claim 1 , wherein in formula I, Pro* is Proline.

3. The topical composition according to claim 1 , wherein Xaa is selected from Leucine (Leu, L) and Arginine (Arg, R), the peptide being X-PPL-Y or X-PPR-Y.

4. The topical composition according to claim 1 , wherein R 2 is an alkyl chain of 1 to 24 carbon atoms.

5. The topical composition according to claim 1 , wherein R 1 and/or R 2 is an alkyl chain of 1 to 24 carbon atoms.

6. The topical composition according to claim 1 , wherein Y is selected from OH, OMe, OEt and NH 2 .

7. The topical composition according to claim 6 , wherein Y is OH.

8. The topical composition according to claim 1 , wherein X is selected from myristoyl (C 14 ) and palmitoyl (C 16 ).

9. The topical composition according to claim 8 , wherein X is myristoyl.

10. The topical composition according to claim 9 , wherein the peptide is selected from Myr-PPL-OH and Myr-PPR-OH.

11. The topical composition according to claim 1 , wherein the backbone of R 1 and/or R 2 comprises a heteroatom selected from O, S, and N.

12. A method for a therapeutical treatment of a skin deficient in molecules constituting the dermal extracellular matrix, comprising applying to the skin of a person in need thereof the topical composition according to claim 1 to stimulate synthesis of at least one molecular constituting the dermal extracellular matrix, wherein each Pro* is proline and Y is OH.

13. A method for a topical cosmetic treatment, comprising applying a topical composition according to claim 1 to skin, wherein each Pro* is proline and Y is OH.

14. The method according to claim 13 , wherein the topical cosmetic treatment is an anti-ageing treatment.

15. The method according to claim 13 , wherein the topical cosmetic treatment is a treatment:

Of wrinkles and fine lines, and/or

For ameliorating the mechanical properties of skin, firming, toning, elasticity, flexibility and suppleness, and/or

For increasing the density and volume of skin (volumating or re-pulping effect), and/or

For restructuring skin,

For fighting strechmarks,

For improving skin barrier, and/or

For skin hydration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2016
From: PESCHARD, OLIVIER; DOUCHET, ANNE; LEROUX, RICHARD; MONDON, PHILIPPE
To: SEDERMA
Reel/Frame 040709/0802 →
Priority Claims (1)
FR 14 54632 · May 22, 2014 · national
Continuity (1)
Related Publication 20170157014A1 · Jun 8, 2017
Cited By (2)
US 12,337,000 US 12,410,143